(Medical Xpress) -- New ways that viruses manipulate the human immune response have been revealed in a research paper just published in Nature involving TCD scientists. Dr Orla Mulhern and Professor Andrew Bowie, School of ...
Aug 3, 2012
0
0
Two new targets have been discovered for antiviral therapies and vaccines strategies that could enhance the body's defenses against such infectious diseases as West Nile and hepatitis C. The targets are within the infection ...
Jul 30, 2012
0
0
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's ...
Jul 9, 2012
0
0
A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of ...
Jan 24, 2012
0
0
A research team led by scientists from The University of Texas MD Anderson Cancer Center have discovered four new "ZIP codes" in their quest to map the vast blood vessel network of the human body.
Oct 24, 2011
0
0
(Medical Xpress) -- This weekend at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, Illinois, researchers from two different study groups, one on the east coast and one on the west coast, ...
Researchers from the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa), Jennerex Inc. and several other institutions today reported promising results of a world-first cancer therapy trial in renowned ...
Aug 31, 2011
3
0
Cancer researchers are a step closer to finding a cure for advanced prostate cancer after effectively combining an anti-cancer drug with a viral gene therapy in vivo using novel ultrasound-targeted microbubble-destruction ...
May 10, 2011
0
0
(Medical Xpress) -- Yale University researchers have identified four unique host defense proteins among thousands that seem to play a crucial role in mobilizing the immune system's response to bacterial infections, they report ...
May 6, 2011
0
0
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity ...
Jul 24, 2024
0
0
